Ann: Imugene completes $90 M placement and launches $5 M SPP, page-7

ASX Announcement
IMUGENE COMPLETES STRONGLY SUPPORTED $90M PLACEMENT & LAUNCHES $5M SPP___________________________________________________________________
•• The placement received outstanding cornerstone interest from specialist biotech institutional investors
*Share Purchase Plan (SPP) for existing eligible shareholders to raise up to a further $5 million at $0.30 per share
*Participants in the placement and SPP will receive 1 free option for every 2 shares received in the offer – the options are intended to be listed on the ASX with an exercise price of $0.45 and expiration of 31 August 2024
* The capital raised will be used to fund Imugene’s clinical trial pipeline through to the end of 2025, with partnering and licensing opportunities and R&D rebates expected to extend the cash runway sophisticated investors at $0.30 per share
Firm commitments received for $90 million placement to new and existing institutional